Episode Details
Back to Episodes
Novo Nordisk 2025 Annual Performance and 2026 Strategic Outlook
Published 5 months, 4 weeks ago
Description
In 2025, Novo Nordisk achieved 10% sales growth, reaching DKK 309 billion, primarily driven by a 31% surge in obesity care. Key developments include the Wegovy pill launch and pipeline assets like CagriSema. The firm announced a DKK 15 billion share buyback and increased dividends.